Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05789082 |
| Title | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRAScendo 170) |
| Acronym | Krascendo 170 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Hoffmann-La Roche |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | SWE | POL | NLD | ITA | ISR | GBR | ESP | CHE | CAN | BRA | BEL | AUS | ARG |